The Goderich, Ontario-based company will lead the agricultural revolution of cannabis genetics, the company said in a statement.
Focusing on Cannabis Genetics
Cambium will focus on developing the next generation of premium cannabis genetics for recreational, medical and wellness applications. The company’s goal is to supply agriculturally-focused, disease resistant, premium seed stock to the global cannabis market.
“Our proprietary genetics selection methodology and ability to cultivate high-end cannabis at scale at 7ACRES has created strong industry demand for our proprietary genetics and cultivation techniques. It was as a result of the demand that we saw a global opportunity to create a company whose sole focus is innovating plant genetics and cultivation IP for the global cannabis market. We believe genetics are the foundation of proprietary cannabis products in the long term,” Supreme Cannabis CEO Navdeep Dhaliwal stated.
“Cambium will develop cultivars that benefit our in-house brands, as well as our domestic and global cultivation and manufacturing partners. Initially, Cambium is expected to benefit from 7ACRES’ established genetics, existing infrastructure and the unparalleled plant knowledge of its team,” Dhaliwal stated.
Cambium Sees Opportunities
Dr. Alan Darlington will lead Cambium as general manager. Dr. Darlington worked at Supreme Cannabis’ subsidiary 7ACRES as the director of special projects where he has been successful in improving the agricultural performance of the company’s genetics.
Dr. Darlington holds a PhD from the University of Guelph in greenhouse systems and has over 30 years of experience working with diverse multidisciplinary teams to develop plant-based IP.
“Cannabis has not yet had the benefit of the agricultural revolution that transformed commercial agriculture on a global scale over the past century. We believe, Cambium will play a leading role in advancing the cannabis industry by revolutionizing strain development to enhance the broader industry’s outputs,” Dr. Darlington stated.
“From the next blockbuster recreational strain, to disease resistant agricultural seed stock, Cambium will seek to improve the economic profile of cannabis production by pushing the boundaries of the cannabis plant,” he added.
Supreme Cannabis will invest approximately $14 million to develop a world-leading facility for cannabis-focused research and innovation. The facility will include the development of proprietary growing rooms for testing and selection of new genetics, breeding rooms for the creation of new seed stock, and supporting infrastructure in the existing 34,000-sq.-ft. facility.
Supreme Cannabis expects to begin the retrofitting of the Cambium facility in the early summer of 2019. The company has started the Health Canada licensing process.